Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zofran (Ondansetron hydrochloride) injection

D W Claussen

    Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates
    |February 1, 1994
    PubMed
    Summary

    Postoperative nausea and vomiting affect 30% of surgical patients. Zofran injection, at 4 mg IV, effectively prevents and reduces these symptoms with minimal side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Aciphex (rabeprazole).

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·2000
    Same author

    Celebrex (celecoxib).

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·2000
    Same author

    Mirapex: pramipexole dihydrochloride tablets.

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·2000
    Same author

    Chemotherapy drugs: an overview for the digestive system.

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·1999
    Same author

    Kenalog-10 (triamcinoclone acetonide).

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·1999
    Same author

    Remicade (infliximab).

    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates·1999

    Area of Science:

    • Anesthesiology
    • Pharmacology
    • Surgical Care

    Background:

    • Postoperative nausea and vomiting (PONV) affect approximately 30% of patients undergoing surgical procedures.
    • Existing treatments for PONV have varying efficacy and side effect profiles.
    • Zofran (ondansetron) has a history of use in managing chemotherapy-induced nausea and vomiting since 1991.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Zofran injection for the prevention of postoperative nausea and vomiting.
    • To determine the optimal dosage and administration route for Zofran in the perioperative setting.

    Main Methods:

    • The Food and Drug Administration (FDA) has granted clearance for marketing Zofran injection for PONV prevention.
    • Clinical studies were conducted to assess Zofran's effectiveness.
    • A specific dosage of 4 mg administered intravenously (IV) over 2 to 5 minutes was investigated.

    Main Results:

    • Zofran injection demonstrated good results in clinical studies.
    • The medication was effective in reducing or preventing postoperative nausea and vomiting.
    • Minimal adverse reactions were observed during the evaluation.

    Conclusions:

    • Zofran injection is a viable option for preventing and managing postoperative nausea and vomiting.
    • The established dosage of 4 mg IV over 2 to 5 minutes appears safe and effective.
    • Further clinical application of Zofran can improve patient outcomes after surgery.

    Related Experiment Videos